BioSante Pharmaceuticals wants to stabilize hormonal ups and downs. The firm is developing topical hormone therapy gels to deliver supplemental estrogen, progestogen, and testosterone. Its Elestrin product is a transdermal estrogen gel used to treat menopausal symptoms, while its Bio-T-Gel treats hypogonadism, a form of testosterone deficiency in men that can cause impotence and bone or muscle weakness. The company's development-stage candidates include a gel to treat female sexual dysfunction (LibiGel), as well as contraceptive-compatible hormone therapies (Pill-Plus). The firm is also developing potential cancer vaccine therapies.